Owczarek Aleksandra, Kołodziejczyk-Czepas Joanna, Marczuk Paulina, Siwek Julia, Wąsowicz Katarzyna, Olszewska Monika Anna
Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Lodz, 90-151 Lodz, Poland.
Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.
Pharmaceuticals (Basel). 2021 Dec 14;14(12):1301. doi: 10.3390/ph14121301.
Horse chestnut () flower is a traditional medicine applied to alleviate symptoms of chronic venous insufficiency (CVI). However, its flavonoid-based composition has not been sufficiently recognized, and the data supporting its traditional application are lacking. In the work, 43 constituents were detected by UHPLC-PDA-ESI-TQ-MS/MS (flavonoids, phenolic acids, flavanols, and coumarins), including 31 reported in the flower for the first time. The quantitative HPLC-PDA study (developed and validated for quality control purposes) indicated the fractionated extraction as an efficient method for enhancing the total polyphenol content (TPHC) in the extracts (up to 414.06 mg/g) and kaempferol glycosides as their dominant constituents (75.05-82.14% TPHC). The activity studies showed significant scavenging properties of the extracts and their constituents towards reactive oxygen species (especially against highly reactive hydroxyl radical, with capacities up to 7.85 mmol ascorbic acid equivalents/g). Moreover, the analytes relevantly protected human plasma biomolecules from peroxynitrite-induced oxidative/nitrative damage; at 1-50 µg/mL, they hindered the protein nitration and lipid peroxidation, decreasing the levels of 3-nitrotyrosine (by up to 50%) and thiobarbituric acid reactive substances (by up to 70%), respectively. The extracts also averted the depletion of plasma thiols (by up to 67%) and improved the non-enzymatic antioxidant capacity of plasma. The demonstrated mechanisms might be partly responsible for the efficacy of the flower in CVI. Additionally, the anti-aggregatory and anticoagulant properties of the extracts were found only mild or negligible, which suggests that they may be safely applied with drugs impacting the coagulation process.
七叶树花是一种用于缓解慢性静脉功能不全(CVI)症状的传统药物。然而,其基于黄酮类化合物的成分尚未得到充分认识,且缺乏支持其传统应用的数据。在这项研究中,通过超高效液相色谱-光电二极管阵列-电喷雾电离-串联四极杆质谱(UHPLC-PDA-ESI-TQ-MS/MS)检测到43种成分(黄酮类化合物、酚酸、黄烷醇和香豆素),其中31种是首次在该花中报道。定量高效液相色谱-光电二极管阵列研究(为质量控制目的而开发并验证)表明,分级萃取是提高提取物中总多酚含量(TPHC)(高达414.06 mg/g)的有效方法,山奈酚苷是其主要成分(占TPHC的75.05-82.14%)。活性研究表明,提取物及其成分对活性氧具有显著的清除特性(尤其是对高活性羟基自由基,清除能力高达7.85 mmol抗坏血酸当量/g)。此外,分析物能有效保护人血浆生物分子免受过氧亚硝酸盐诱导的氧化/硝化损伤;在1-50 µg/mL浓度下,它们分别抑制蛋白质硝化和脂质过氧化,使3-硝基酪氨酸水平(降低高达50%)和硫代巴比妥酸反应性物质水平(降低高达70%)降低。提取物还能避免血浆硫醇的消耗(降低高达67%),并提高血浆的非酶抗氧化能力。所证明的机制可能部分解释了该花在CVI治疗中的疗效。此外,发现提取物的抗聚集和抗凝特性仅为轻度或可忽略不计,这表明它们可与影响凝血过程的药物安全联合应用。